French Retail REITs Stock News

MedinCell (ENXTPA:MEDCL) has been in focus after partner Teva filed a New Drug Application with the U.S. FDA for its olanzapine long acting injectable, which is built on MedinCell’s BEPO technology. See our latest analysis for MedinCell. The latest regulatory milestone appears to have reignited interest in MedinCell, with the 1 day share price return of 3.85 percent and a 90 day share price return of 41.39 percent contributing to a robust 1 year total shareholder return of 77.19 percent. This...

In recent months, ARGAN announced a new lease with JUNG LOGISTIQUE for a 30,000 sq.m AutOnom® logistics facility in Tournan-en-Brie and confirmed with DECATHLON the modernization of heating systems across more than 170,000 sq.m of logistics space using next-generation heat pumps. These projects underline ARGAN’s focus on pairing logistics expansion with concrete energy-efficiency upgrades, enhancing the resilience and decarbonization profile of its tenant portfolio. We’ll now examine how...

TotalEnergies (ENXTPA:TTE) has been grinding higher over the past month, outpacing many European energy peers as investors reassess its mix of traditional oil assets and growing renewables exposure, with the stock still trading at a moderate valuation. See our latest analysis for TotalEnergies. At around $55.82, the recent pullback after a steady 30 day share price return of 3.29% sits against a solid 10.89% 1 year total shareholder return, suggesting momentum is cooling slightly rather than...

EssilorLuxottica recently created a high-profile Scientific Advisory Committee of globally recognized experts in physics, ophthalmology, audiology, mathematics and bioethics to guide its research in areas such as oculomics, AI and optics. This move signals a deeper push to fuse advanced science with wearable technology, potentially sharpening the company’s edge in AI-powered eyewear and broader health-focused innovation. We’ll now examine how EssilorLuxottica’s new Scientific Advisory...

H&K AG reported past earnings results for the nine months ended September 30, 2025, with sales rising to €279.1 million from €253.6 million and net income increasing to €24 million from €17 million, lifting basic earnings per share from continuing operations to €0.68 from €0.48 a year earlier. This improvement in profitability suggests that H&K AG converted higher revenues into stronger earnings, which can influence how investors view its operational efficiency. We will now examine how H&K...

Earlier this month, CONMEBOL announced Atos as its first Official Innovation Partner for major South American club competitions, tasking the company with building new digital platforms to deepen fan engagement, while Atos also unveiled a joint research program to strengthen AI security and expanded its sports-technology push in Saudi Arabia. Together, these moves highlight how Atos is leaning on sports technology and secure AI capabilities to reposition its business mix toward higher-value...

If you have been wondering whether Eurofins Scientific is still a quality stock at a fair price, you are not alone, as many investors are trying to figure out if the current share price matches its long term potential. Despite a choppy few weeks, with the share price down 4.4% over the last 7 days and 2.6% over the last month, Eurofins is still up 16.3% year to date and 20.2% over the past year. This hints that the market may be warming back up to its story after a tougher 3 and 5 year...

Key Insights Significantly high institutional ownership implies AXA's stock price is sensitive to their trading actions...

Wondering if Ipsen is still a smart buy after its strong multi year run, or if most of the upside is already priced in? This breakdown will help you decide whether the current tag looks compelling or stretched. The stock has been roughly flat over the last week and month, but it is still up 9.2% year to date, 13.5% over the past year, and a hefty 90.2% over five years, which naturally raises questions about future return potential and changing risk perceptions. Recent headlines have focused...

L'Oréal (ENXTPA:OR) has quietly pushed higher, with the share price drifting up over the past month despite some choppiness in the past 3 months, and that mix deserves a closer look. See our latest analysis for L'Oréal. Zooming out, L'Oréal's 30 day share price return of 3.9 percent and year to date share price gain near 9 percent suggest steady, if unspectacular, momentum as investors weigh its resilient growth against a demanding valuation. If you are comparing L'Oréal with other consumer...

SPIE (ENXTPA:SPIE) is pushing deeper into cybersecurity with its acquisition of German specialist Cyqueo, a move that tightens its grip on complex IT security projects in a structurally growing market. See our latest analysis for SPIE. The Cyqueo deal lands as SPIE’s share price has climbed to about €47.24, with strong year to date share price returns and a robust multi year total shareholder return. This suggests momentum is building as investors increasingly price in growth and execution on...

Kering (ENXTPA:KER) has quietly outperformed over the past 3 months, even as the share price has slipped about 4% this month, prompting investors to reassess what is already priced into the stock. See our latest analysis for Kering. Zooming out, Kering’s recent pullback sits against a much stronger backdrop, with a roughly 23% 3 month share price return and a 1 year total shareholder return of about 23%. This suggests that sentiment has improved but is now pausing to reassess growth and brand...

Alstom (ENXTPA:ALO) has just confirmed that French government funding for its IPCEI backed hydrogen projects is being pulled. This has prompted the group to suspend related work while it negotiates alternatives with authorities. See our latest analysis for Alstom. The news lands after a strong short term rebound, with a 7 day share price return of 7.7 percent and a 30 day gain of 14.6 percent. However, the 5 year total shareholder return remains sharply negative, suggesting recent momentum is...

Eurazeo (ENXTPA:RF) just rolled out two new Evergreen funds, EPIC for private debt and EPSO for secondary private equity, extending its Wealth platform across key European markets in line with its 2024 to 2027 strategy. See our latest analysis for Eurazeo. The launch of EPIC and EPSO comes as the share price hovers around €54.5, with a 7 day share price return of 3.1 percent. However, the year to date share price return remains nearly 25 percent lower, suggesting long term total shareholder...

Ipsos (ENXTPA:IPS) just announced that long standing CFO Dan Lévy is stepping down, with internal executive Olivier Champourlier stepping in as interim finance chief, a leadership shift investors will watch closely. See our latest analysis for Ipsos. The leadership change lands at a sensitive time, with the share price at €32.4 and a steep year-to-date share price return of around negative 30 percent. The three-year total shareholder return of roughly negative 36 percent signals fading...

Renault (ENXTPA:RNO) has quietly bounced around 5 % over the past week, even though the shares are still down sharply this year. This invites a closer look at whether the current price reflects its fundamentals. See our latest analysis for Renault. The recent 7 day share price return of 5.46 percent, on top of a 7.31 percent 30 day share price gain, suggests momentum is tentatively rebuilding even though the year to date share price return remains negative and the 1 year total shareholder...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

As the European market experiences mixed returns with a slight uptick in the STOXX Europe 600 Index amid hopes for interest rate cuts, investors are keenly observing inflation trends and economic growth revisions across the region. In this dynamic environment, dividend stocks can offer stability and income potential, making them a compelling consideration for those looking to navigate these uncertain times.

Exosens (ENXTPA:EXENS) just locked in a longer runway with Theon International by extending their image intensifier supply deal through 2030, turning future options into firm orders and backing ongoing capacity expansion. See our latest analysis for Exosens. The deal lands while Exosens trades around €48.9, after a powerful year to date share price return of 154.24 percent and a 1 year total shareholder return of 166.59 percent, suggesting momentum is still firmly building as investors...

Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...

Grenobloise d'Electronique et d'Automatismes Société Anonyme's (EPA:GEA) stock is up by a considerable 13% over the...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Abivax, a France-based clinical-stage biotech, previously reported that its lead candidate obefazimod achieved statistically significant remission rates in phase 3 trials for moderate to severe ulcerative colitis, including patients with inadequate responses to prior therapies. The company now plans a U.S. regulatory submission for obefazimod in the second half of 2026, potentially opening the door to additional inflammatory bowel disease indications such as Crohn’s disease. We’ll explore...

Capgemini (ENXTPA:CAP) just landed a multi year EU cybersecurity framework contract and paired it with fresh TechnoVision 2026 trend insights, a one two combination that sharpens its digital transformation narrative for investors. See our latest analysis for Capgemini. The market seems to be warming back up to that story, with a 30 day share price return of 19.34 percent and a 90 day gain of 20.21 percent, even though the one year total shareholder return is still slightly negative. If...